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ABSTRACT
ADAMTS-1 is an extracellular protease with critical roles in
organogenesis and angiogenesis. Here we demonstrate a functional
convergence of ADAMTS-1 and the transmembrane heparan sulfate
proteoglycan syndecan-4 in influencing adhesion, migration and
angiogenesis. Knockdown of ADAMTS-1 in endothelial cells resulted
in a parallel reduction in cell surface syndecan-4, attributable to
increased matrix metalloproteinase-9 (MMP9) activity. Knockdown of
either ADAMTS-1 or syndecan-4 increased cellular responses to
vascular endothelial growth factor A isoform VEGFA164, and increased
ex vivo aortic ring microvessel sprouting. On fibronectin, knockdown of
either protein enhanced migration and promoted formation of long α5
integrin-containing fibrillar adhesions. However, integrin α5 null cells
still showed increased migration in response to ADAMTS-1 and
syndecan-4 siRNA treatment. Plating of naïve endothelial cells on cell-
conditioned matrix from ADAMTS-1 and syndecan-4 knockdown cells
demonstrated that the altered adhesive behaviour was matrix
dependent, and this correlated with a lack of expression of fibulin-1:
an extracellular matrix co-factor for ADAMTS-1 that is known to inhibit
migration. These findings support the notion that ADAMTS-1 and
syndecan-4 are functionally interconnected in regulating cell migration
and angiogenesis, via collaboration with MMP9 and fibulin-1.
This article has an associated First Person interview with the first
author of the paper.
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INTRODUCTION
The ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motifs) family of extracellular proteases includes
19 members in humans, with diverse roles in tissue development
and homeostasis (Kuno et al., 1997; Porter et al., 2005). Their
essential functions are underlined by the recognition that several
family members are encoded by genes that are responsible for
inherited genetic disorders when mutated, while others are
associated with pathologies including cancer, arthritis and
cardiovascular disease when aberrantly expressed (Hubmacher
and Apte, 2015; Kelwick et al., 2015b; Mead and Apte, 2018).
The ADAMTSs are zinc-dependent metalloproteinases with a
compound domain structure, each possessing a catalytic domain
containing the metalloproteinase and disintegrin-like features,
followed by a modular ancillary domain that differs between
subgroups of family members and is important for their biological
actions (Kuno et al., 1997; Porter et al., 2005). The largest clade in the
ADAMTS family are identified as proteoglycanases that can cleave a
variety of proteoglycans, including versican, aggrecan and brevican, as
well as other extracellular matrix proteins (Hubmacher andApte, 2015;
Kelwick et al., 2015b). First discovered in 1997, ADAMTS-1 is the
prototype of the family and amember of the proteoglycanase clade that
also includes ADAMTS-4, -5, -8, -9, -15 and -20. The ability of
ADAMTS-1 to cleave structural extracellular matrix (ECM)
components is physiologically relevant as demonstrated by
Adamts1−/− knockout mice, which exhibit abnormally high rates of
perinatal lethality due to multiple organ defects, in particular severe
kidney malformation and cardiac defects (De Arao Tan et al., 2013;
Krampert et al., 2005). The surviving female mice suffer from
infertility, due to the ineffective cleavage of versican during ovarian
maturation (Krampert et al., 2005; Mittaz et al., 2004; Shindo et al.,
2000).
However, as well as its proteolytic function, ADAMTS-1 also
interacts with other proteins including latent TGF-β (Bourd-Boittin
et al., 2011) and fibulin-1, which acts as a co-factor (Lee et al.,
2005). ADAMTS-1 has many context-dependent effects in
biological processes such as migration, invasion and cell
signalling, which are relevant to its impact on physiology and
pathophysiology, indicating it acts through multiple mechanisms
(De Arao Tan et al., 2013). This is reflected in its anti-angiogenic
actions, which involve both proteolytic and non-proteolytic
mechanisms, the former by mediating the release of highly
anti-angiogenic fragments of thrombospondin (TSP)-1 and -2
(Gustavsson et al., 2010; Lee et al., 2006) and the latter via direct
binding and sequestration of the vascular endothelial growth factor
isoform VEGFA165 (Fu et al., 2011; Luque et al., 2003).
Another significant proteoglycan partner of ADAMTS-1 is
syndecan-4 (Rodríguez-Manzaneque et al., 2009). Syndecan-4 is a
ubiquitously expressed heparan sulfate proteoglycan that acts as a key
mediator of several cellular processes including adhesion, proliferation
and endocytosis (Couchman and Woods, 1999; Elfenbein and
Simons, 2013; Elfenbein et al., 2012). Its heparan sulfate
glycosaminoglycan (GAG) chains provide binding sites for heparin-
binding growth factors such as fibroblast growth factors (FGFs),
platelet-derived growth factors (PDGFs) and vascular endothelial
growth factors (VEGFs) (Elfenbein and Simons, 2013). The binding
of these growth factors to syndecan-4 can have several consequences:
activation of cellular signalling can occur through syndecan-4 actingReceived 1 July 2019; Accepted 20 January 2020
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as a co-receptor that presents the growth factor ligand to its signalling
receptor, as in the case of FGF, or there can be direct activation of
downstream signalling mediated by syndecan-4 itself, such as protein
kinase Cα (PKCα) (Oh et al., 1997a,b). In addition, syndecan-4 can
regulate growth factor bioavailability by acting as a cell-bound
reservoir that can be released by subsequent proteolytic cleavage
(Bergers et al., 2000; Ramnath et al., 2014). In addition to its role as a
signalling regulator, syndecan-4 is also a key mediator in focal
adhesion formation. Fibroblasts from syndecan-4 null mice exhibit
impaired adhesion to fibronectin (Ishiguro et al., 2000). Via the
binding and activation of PKCα, syndecan-4 facilitates α5β1 integrin
binding to its substrate fibronectin, allowing maturation of focal
adhesions (Bass et al., 2007; Mostafavi-Pour et al., 2003). Given its
key role as a nexus of signalling and adhesion mechanisms, the
relative levels and localisation of syndecan-4 are therefore critical
determinants of cellular behaviour.
Several reports have connected the actions of ADAMTS enzymes
with syndecan-4 (SDC4), including ADAMTS-1 and -4 (Rodríguez-
Manzaneque et al., 2009), ADAMTS-5 (Echtermeyer et al., 2009;
Wang et al., 2011), ADAMTS-6 and -10 (Cain et al., 2016) and
ADAMTS-15 (Kelwick et al., 2015a). In this study, we have
uncovered details of a complex inter-relationship between
ADAMTS-1 and syndecan-4 in murine fibroblasts and endothelial
cells. We have shown that acute depletion of ADAMTS-1 leads to a
concomitant reduction in cell surface levels of syndecan-4, such that
downregulation of either syndecan-4 or ADAMTS-1 has similar
consequences on cell behaviour, shown by increases in cellular
migration and striking changes to focal adhesions, both of whichwere
fibronectin dependent. Furthermore, loss of either ADAMTS-1 or
syndecan-4 in endothelial cells led to increases in angiogenesis,
which we demonstrate is due to reduced ability of cells to sequester
the pro-angiogenic growth factor VEGFA164. Moreover, these effects
have downstream consequences on α5 integrin trafficking, but α5
integrin is not essential for them to occur. These results demonstrate
the existence of an interplay between ADAMTS-1 and syndecan-4
that orchestrates cell adhesion, migration and angiogenesis.
RESULTS
Knockdown of ADAMTS-1 results in reduction of cell surface
syndecan-4
We have used small interfering RNA (siRNA) to deplete either
ADAMTS-1 or syndecan-4 in murine 3T3 fibroblast cells (3T3s)
and lung microvascular polyoma middle T-antigen immortalised
endothelial cells (ECs). mRNA knockdown was confirmed using
TaqMan quantitative PCR (qPCR) (Fig. S1). Our initial hypothesis
was that as ADAMTS-1 has been reported to cleave the N-terminal
domain of syndecan-4, depletion of ADAMTS-1 would result in
accumulation of syndecan-4 on the cell surface (Rodríguez-
Manzaneque et al., 2009). However, flow cytometric analysis
revealed that siRNA knockdown of ADAMTS-1 resulted in a
significant concomitant decrease in cell surface syndecan-4,
equivalent to that seen with syndecan-4 knockdown (Fig. 1A). To
confirm this visually, immunocytochemistry was performed;
however, as in our hands staining using commercially available
syndecan-4 antibody was unsuccessful, cells were transfected with a
HA-tagged syndecan-4 construct (HA-SDC4). This confirmed
reduced cell surface HA-SDC4 display in ADAMTS-1-depleted
cells when compared with cells treated with non-targeting control
siRNA (Fig. 1B). To confirm that the interaction was specific to
ADAMTS-1 and syndecan-4, levels of other endothelial expressed
syndecans were recorded following ADAMTS-1 and syndecan-4
siRNA depletion. Syndecan-3 was not expressed in ECs; syndecan-1
and -2 were, but the cell surface levels of these proteins were
unaffected by ADAMTS-1 or syndecan-4 siRNA depletion (Fig. S2).
To elucidate the mechanism by which ADAMTS-1 regulates
syndecan-4 expression, we first investigated whether knockdown of
ADAMTS-1 led to changes in Sdc4 gene expression. ADAMTS-1
siRNA did not alter Sdc4 expression at the RNA level (Fig. S1).
Therefore, we hypothesised that loss of cell surface syndecan-4
could be a result of changes in membrane trafficking, so we carried
out cell surface biotinylation-based internalisation and recycling
assays. ECs were surface labelled with cleavable biotin, incubated
for time intervals to allow internalisation, then biotin remaining
on the cell surface was cleaved. Syndecan-4 internalisation was
quantified by a syndecan-4 capture enzyme-linked immunosorbent
assay (ELISA) and biotin detection using streptavidin (Fig. 1C). For
the recycling assay cells were incubated further, to allow
biotinylated protein to recycle to the surface (Fig. 1D). These
experiments demonstrated that neither the rate of syndecan-4
internalisation nor levels of recycling to the membrane were
changed as a result of ADAMTS-1 knockdown.
Loss of cell surface syndecan-4 is MMP9 dependent
As reduced syndecan-4 levels did not appear to be a result of altered
transcription or membrane trafficking, we speculated that the
decreased cell surface syndecan-4 was a result of increased
shedding. As matrix metalloproteinases (MMPs) are known
cleavers of syndecans, they were considered as possible mediators
of this shedding (Manon-Jensen et al., 2010). ECs were treated with
one of the following three broad-spectrum MMP inhibitors: BB-94,
CT-1746, GM 6001 or a DMSO vehicle control. Treatment with any
of the three MMP inhibitors resulted in accumulation of syndecan-4
at the cell surface, and in cells treated with a combination of an
MMP inhibitor and ADAMTS-1 siRNA, syndecan-4 levels were
not significantly reduced (Fig. 2A). This suggests that MMPs are
responsible for the reduction in cell surface syndecan-4 seen in
response to loss of ADAMTS-1.
To identify the specific enzyme responsible, a panel of MMPs
known to be expressed in endothelial cells were profiled: MMP2,
MMP9,MMP14 (MT1-MMP) and ADAMTS-4 (Bergers et al., 2000;
Genís et al., 2006; Hsu et al., 2012). ADAMTS-1 siRNA knockdown
resulted in significantly increased expression ofMmp9 compared with
non-targeting control (NTC) or syndecan-4 siRNA-treated cells, which
expressed almost noMmp9. In both treated and untreated cells,Mmp2,
Mmp14 and Adamts4 expression was unchanged (Fig. 2B). The
increase in Mmp9 RNA expression was reflected in increased MMP9
activity, as shown by gelatin zymography of conditioned media from
ADAMTS-1 siRNA-, syndecan-4 siRNA- and NTC-treated cells
(Fig. 2C). In these experiments we were unable to detect syndecan-4
that had been shed from the cell surface into the medium under any
conditions, indicating that this is probably rapidly degraded. However,
treatment with MMP9 siRNA (Fig. 2D) or MMP9 specific inhibitor
SB-3CT (Fig. 2E) was sufficient to reverse the phenotype resulting
from ADAMTS-1 knockdown. This demonstrates that increased
expression of MMP9, known to cleave syndecan-4, is directly
responsible for the reduced syndecan-4 levels seen after ADAMTS-1
siRNA treatment (Ramnath et al., 2014; Reine et al., 2019).
Syndecan-4 contributes to sequestration of VEGFA165
by ADAMTS-1
ADAMTS-1 acts as an inhibitor of angiogenesis by sequestering
VEGFA164, a key pro-angiogenic factor. This sequestration prevents
VEGF from binding and activating its major receptor VEGFR2
(Luque et al., 2003). ADAMTS-1 exclusively binds VEGFA164,
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Fig. 1. ADAMTS-1 regulates syndecan-4 expression but not via altered recycling or internalisation. (A) Flow cytometric analysis of syndecan-4 (SDC4)
surface levels on lung microvascular endothelial cells (ECs) and 3T3 fibroblast cells (3T3s) treated with non-targeting control (NTC), SDC4 or ADAMTS-1
siRNA. The graph (far right) is a representative histogram showing median fluorescence intensity. Values were calculated after gating on forward and side scatter
and normalised to isotype controls; n=3 biologically independent experiments. Charts show means±s.e.m., *P<0.05 compared with control cells by Student’s
t-test. (B) Representative image of HA-tag (red) and DAPI (blue) immunostained ECs expressing HA-tagged SDC4 treated with siRNA against ADAMTS-1
or NTC on fibronectin; n=3 independent experiments. Scale bars, 20 µm. (C) SDC4 internalisation assay; EC cell surface proteins were biotinylated using a
cleavable, membrane non-permeable biotin. ECs were incubated to allow biotinylated proteins to internalise for indicated time intervals. Following this, cell
surface biotin was removed using the reducing agent MesNa, leaving only membrane proteins that had been internalised and biotinylated. ECs were lysed and
protein was collected prior to internalisation, and at 5, 10 and 15 min of internalisation. An SDC4 capture ELISA was performed on lysed ECs. Streptavidin was
used to detect biotinylated SDC4. Graphs indicate the percentage of internalised biotinylated syndecan-4, relative to starting level of cell surface syndecan-4
(n=3, bars represent s.e.m.). (D) SDC4 recycling assay; ECs were cell surface biotinylated, and membrane proteins were then allowed to internalise for 20 min,
followed by MesNa treatment, to remove cell surface biotin. After the MesNa treatment, internalised biotin was allowed to return to the cell surface. Biotinylated
protein that had returned to the surface was again removed using MesNa and an ELISA was performed as in panel C. Values represent percentage of
recycled syndecan-4 relative to total internalised after 20 min (n=3 independent experiments, bars represent s.e.m.).
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and the interaction is dependent on the heparin-binding domain.
Previous work by Iruela-Arispe et al. has suggested that a heparin
sulfate proteoglycan such as a member of the syndecan family may
provide a bridge to facilitate this interaction (Iruela-Arispe et al.,
2003). Alternatively, syndecan-4 may function as co-receptor for
VEGF in an interaction similar to that reported for FGF2; however,
although syndecan-2 endothelial specific deletion in mice leads to
arteriogenic defects and impaired VEGF signalling, no such
abnormalities are observed in mice with a deleted syndecan-4
(Corti et al., 2019; Horowitz et al., 2002).
To determine if syndecan-4 is capable of binding VEGFA164,
co-immunoprecipitations were performed. Immunoprecipitation (IP) of
VEGFA164 was able to co-precipitate syndecan-4, revealing that
syndecan-4 either directly or indirectly binds VEGF. When cells
were treated with ADAMTS-1 siRNA, less syndecan-4 was found
upon co-precipitation (Fig. 3B,C). The reduction in syndecan-4
seen with ADAMTS-1 siRNA may be an indicator that the
interaction involves ADAMTS-1; however, it may also be a result of
the reduced cell surface syndecan-4 seen with ADAMTS-1 siRNA
treatment.
We next sought to establish if syndecan-4 supported signalling, or
aided in the sequestration of VEGF by ADAMTS-1, by examining
impact of ADAMTS-1 or syndecan-4 siRNA on VEGF signalling.
Endothelial cells were serum-starved for 3 h, then stimulated with
30 ng/ml VEGFA164 (the mouse equivalent of human VEGFA165).
Cells were lysed at 0, 5, 15 and 30 min post-stimulation, and lysates
collected were run on a western blot to look for changes in the VEGF
signalling pathway. Upon siRNA knockdown of either ADAMTS-1
or syndecan-4, increased phospho-VEGFR2 and phospho-
extracellular signal-related kinase (ERK) were seen, indicating an
increase in cellular responsiveness to exogenous VEGFA165 when
ADAMTS-1 or syndecan-4 levels are reduced (Fig. 3A; Fig. S3).
These data suggest that syndecan-4 binds and sequesters
VEGFA165 alongside ADAMTS-1; this hypothesis was further
investigated using a VEGF ELISA to assess how much VEGF cells
were able to sequester. As before, 30 ng/ml VEGFA164 was added
to ECs cooled to 4°C to prevent signalling. A western blot was
performed to confirm that signalling pathways were not activated
(Fig. S4A), and qPCR confirmed Vegfa mRNA levels were
unchanged (Fig. S4B). The cells were kept at 4°C for 30 min to
allow binding. The medium was then collected and an ELISA was
performed to quantify the amount of unbound VEGF remaining in
the medium.When cells were treated with ADAMTS-1, syndecan-4
or both siRNAs, the amount of free VEGF remaining in the medium
significantly increased (Fig. 3D). Taken together, these data
suggest that the loss of ADAMTS-1 or syndecan-4 prevents the
sequestration of VEGF, leaving it freely available to activate
downstream signalling pathways.
ADAMTS-1 and syndecan-4 sequestration of VEGF inhibits
angiogenesis
The physiological relevance of the ability of ADAMTS-1 and
syndecan-4 to sequester VEGF was investigated. The process of
angiogenesis requires both proliferation and migration of endothelial
cells, which can be stimulated byVEGF. Bromodeoxyuridine (BrdU)
labelling of siRNA-treated cells revealed increased proliferation
in ADAMTS-1-depleted cells, but not syndecan-4-depleted cells
(Fig. 4A). As syndecan-4 is known to interact with numerous other
growth factors (FGFs, EGFs, PDGFs) this may be a result of multiple
pathway involvement (Harburger and Calderwood, 2008).
As conflicting reports exist with regard to the roles of ADAMTS-1
and syndecan-4 in cell migration (Bass et al., 2007; Krampert et al.,
2005; Obika et al., 2012; Rodríguez-Manzaneque et al., 2009),
random migration assays were carried out on siRNA-depleted cells to
assess the effects of their knockdown on motility. siRNA-treated
endothelial cells were plated on either 10 µg/ml collagen I or 10 µg/ml
fibronectin, and time-lapse microscopy was performed over a period
of 16 h to track cell migration. Migration speed was significantly
increased with both ADAMTS-1 and syndecan-4 on fibronectin
matrices only (Fig. 4B).
To see if the altered proliferation and migration resulted in a
corresponding increase in angiogenesis, the mouse aortic ring assay
was utilised. Aortae were harvested from 6- to 8-week-old mice,
sliced into rings and treated with siRNA against ADAMTS-1 or
syndecan-4. The rings were embedded in matrix, and the number of
sprouts that formed was used as a marker of angiogenesis (Baker
et al., 2012). Both siRNAs successfully depleted their targets in the
aortic rings (Fig. 4C). Both ADAMTS-1 and syndecan-4 depletion
resulted in a marked increase in VEGF-dependent new vessel
sprouting (Fig. 4D,E), demonstrating a physiologically relevant effect
of the sequestration of VEGF by ADAMTS-1 and syndecan-4.
Adhesions are altered in ADAMTS-1 and syndecan-4 siRNA
cells on fibronectin matrices
As knockdown of either ADAMTS-1 or syndecan-4 led to altered
migration speeds on fibronectin but not on collagen I, focal
adhesion parameters were assessed on both matrices. Cells were
seeded on a collagen I or fibronectin matrix for 90 or 180 min.
Staining for paxillin was performed to visually assess focal
adhesions, and their size and number were calculated using
ImageJ. While on both collagen and fibronectin the numbers of
focal adhesions were unchanged in siRNA-depleted cells,
adhesions to fibronectin matured more quickly. At 90 min post-
adherence to fibronectin, the average focal adhesion size was
larger, with a higher percentage of adhesions reaching a more
mature stage (Fig. 5A,B). The majority of adhesions remained as
small nascent adhesions (<2 µm2) (NTC: 95.6%; syndecan-4:
90.9%; ADAMTS-1: 92%); however, a higher percentage of cell
adhesions in siRNA-treated cells had developed into focal
adhesions (2–6 µm2) (NTC: 4.3%; syndecan-4: 8.5%;
ADAMTS-1: 7.2%). By 180 min this difference no longer
existed, suggesting that the siRNA-treated cells do not form
more large adhesions, but rather their adhesions mature at a faster
rate. Adhesions to collagen were unaffected (Fig. S5), confirming
that the observed effects are due to interaction with the fibronectin
matrix. These changes in focal adhesions of ADAMTS-1 or
syndecan-4 knockdown cells on fibronectin were also apparent in a
marked increase in paxillin signalling in response to VEGF
(Fig. 5C; Fig. S6). This supports the proposition that ADAMTS-1
and syndecan-4 act to sequester VEGF, reducing its
bioavailability, and that their depletion leads to enhanced VEGF
signalling and subsequent changes to focal adhesion morphology.
α5 Integrin localisation is disrupted in the absence of
ADAMTS-1 or syndecan-4
As our data showed perturbation of fibronectin-dependent adhesions
following ADAMTS-1 or syndecan-4 depletion, the contribution of
α5 integrin (α5), the major fibronectin receptor in nascent focal
adhesions in endothelial cells, was considered. Immunocytochemical
visualisation of α5 revealed the development of long, fibrillar-like
adhesions after 180 min adherence to fibronectin in cells treated with
ADAMTS-1 or syndecan-4 siRNA, as opposed to the more
traditional α5 localisation in focal adhesions (<6 µm2) seen in NTC
cells (Fig. 6A).
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As syndecan-4 is known to play a role in integrin surface
trafficking, biotinylation-based internalisation assays were performed
as before, to assess α5 membrane trafficking (Morgan et al., 2013).
To quantify internalisation, immunoprecipitation of biotin followed
by western blot detection of α5 was carried out. Western blotting
revealed an increase in total cell surface α5 in ADAMTS-1 and
syndecan-4 siRNA-treated cells, as well as decreased levels of
internalisation, suggesting that the altered adhesions may be a result
of α5 accumulation due to impaired internalisation (Fig. 6B,C). To
test whether this retention of α5 on the cell surface in ADAMTS-1
and syndecan-4 knockdown cells was responsible for the altered cell
characteristics, we again performed the experiments above in α5-null
endothelial cells treated with ADAMTS-1 or syndecan-4 siRNA.
However, although α5-null endothelial cells showed reduced
migration compared with their wild-type counterparts, the same
phenotypes of increased rates of migration and focal adhesion
maturation, and decreased VEGF sequestration followingADAMTS-
1 or syndecan-4 knockdown were maintained (Fig. 6D). These data
suggest that the changes in α5 integrin are probably a downstream
consequence of changes in cell behaviour mediated by ADAMTS-1
and syndecan-4 knockdown, rather than α5 integrin being the key
effector of the phenotypes.
EC behaviour and signalling phenotypes are maintained in
response to conditioned matrix
As the mechanism by which ADAMTS-1 and syndecan-4 siRNA
increased cell migration and changed focal adhesions was not
dependent on integrin α5, modulation of the ECM itself was
Fig. 2. ADAMTS-1 siRNA-mediated
loss of surface SDC4 is dependent
on MMP activity. (A) Flow cytometric
analysis of SDC4 cell surface levels.
ECs were transfected with NTC or
ADAMTS-1 siRNA, then treated with
an MMP inhibitor: BB-94, CT1746,
GM 6001 or DMSO vehicle control.
Bar chart shows percentage SDC4
expression relative to NTC DMSO-
treated cells (n=3, *P<0.05, **P<0.01,
compared with control cells by
Student’s t-test). (B) TaqMan qPCR
for MMP2, MMP9, MMP14 and
ADAMTS4 on RNA from ECs treated
with NTC, SDC4 or ADAMTS1 siRNA.
Bar chart shows relative expression,
normalised to a housekeeping control
(18S) (n=4 independent experiments,
*P<0.05 compared with control by
Student’s t-test). (C) A representative
gelatin zymogram showing MMP9
activity in the conditioned media of
siRNA-treated ECs. (D) Flow
cytometric analysis of SDC4 surface
levels. ECs were transfected with
MMP9, or a combination of MMP9 and
ADAMTS-1 siRNA. Bar chart shows
percentage SDC4 expression relative
to NTC siRNA-treated cells (n=3
independent experiments). (E) Flow
cytometric analysis of SDC4 following
NTC, SDC4 or ADAMTS1 siRNA
depletion and treatment with MMP9
inhibitor SB-3CT (n=3 independent
experiments).
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considered, especially as these responses were reliant on the cells
being on a fibronectin matrix. In order to assess this, experiments
were performed using ‘conditioned matrix’ (CM) from siRNA-
treated cells that were seeded onto glass coverslips and allowed to
produce matrix for 48 h, following which the siRNA-treated cells
were then stripped away, leaving behind CM. Untreated cells were
seeded onto the CM and left to adhere for 3 h, and then
immunocytochemistry for α5 integrin was carried out. The
phenotype of long, fibrillar adhesions was repeated, indicating
that α5 integrin changes occur in response to a modified matrix
(Fig. 7A). Signalling was examined in a similar fashion: untreated
cells were adhered to CM for 45, 90 and 180 min, then cells were
lysed and signalling responses examined. Cells adhered to the
conditioned matrix from ADAMTS-1 or syndecan-4 knockdown
cells showed increased paxillin and ERK signalling, suggesting that
the altered matrix is sufficient to induce the more migratory
phenotype (Fig. 7B; Fig. S7).
Fibulin-1, a co-factor for ADAMTS-1 and a matrix protein that
has been reported to inhibit migration, showed enhanced expression
at 180 min post-adhesion to fibronectin in NTC-treated cells, but not
ADAMTS-1- or syndecan-4 siRNA-treated cells (Fig. 7C; Fig. S8)
(Lee et al., 2005; Twal et al., 2001). These data support a
mechanism by which ADAMTS-1 and syndecan-4 regulate
adhesion by inducing expression of the matrix protein fibulin-1.
DISCUSSION
Our work provides new insights into a functional connection
between ADAMTS-1 and the cell surface proteoglycan syndecan-4.
Knockdown of either protein via siRNA results in similar responses
with regard to angiogenesis, cell migration and integrin α5
trafficking. Our data support the notion that ADAMTS-1 is an
inhibitor of angiogenesis, and we offer novel data that this occurs in
co-ordination with syndecan-4.
Previous work has shown that ADAMTS-1 inhibits angiogenesis
through direct sequestration of the major pro-angiogenic growth
factor VEGF165, reducing its bioavailability (Luque et al., 2003).
This has also been shown to be true for ADAMTS-4, which can
bind VEGF and inhibit angiogenesis in a similar fashion to
Fig. 3. SDC4 contributes to the
sequestration of VEGFA164 by
ADAMTS-1. (A) VEGF signalling time
course. siRNA-treated ECs were adhered
overnight on fibronectin. Serum-starved
cells were stimulated with 30 ng/ml VEGF
for 0, 5, 15 and 30 min. Western blots were
performed on lysates with anti-VEGFR2,
anti-ERK, and their phosphorylated forms.
HSC70 was used as a loading control. Blot
is representative of four independent
experiments. (B)Western blot using an anti-
SDC4 antibody on fractions from VEGF
immunoprecipitations (IPs) carried out on
HUVECs with lentiviral silencing targeting
NTC, ADAMTS-1 or SDC4. (C) ImageJ
densitometric quantification of IP western
blots (n=3 independent experiments, charts
show means±s.e.m., **P<0.01,
****P<0.0001 compared with control cells
by Student’s t-test). (D) VEGF
sequestration ELISA on ECs treated with
NTC, SDC4 or ADAMTS-1 siRNA. Cells
were kept at 4°C, incubated in serum-free
medium containing 30 ng/ml VEGFA164 for
30 min. Medium was collected and a VEGF
sandwich ELISA was performed to detect
unbound VEGF (n=3 independent
experiments, bars represent s.e.m.,
*P<0.05, **P<0.01 compared with control
cells by Student’s t-test).
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ADAMTS-1 (Hsu et al., 2012). The heparin binding domain of
VEGF165 is necessary for its interaction with ADAMTS-1, and
work by Iruela-Arispe et al. has suggested that this interaction may
be reliant on a heparin-like molecule (Iruela-Arispe et al., 2003).
One such candidate is syndecan-4, a heparan sulfate proteoglycan
and the major syndecan in endothelial cells, known to interact with
heparin-binding growth factors such as VEGFs, PDGFs and FGFs
(Harburger and Calderwood, 2008). Thus, given the numerous
connections between ADAMTS-1 and syndecan-4 and the
dependence of ADAMTS-15 on syndecan-4 to enhance migration
ability, we sought to investigate the relationship between syndecan-
4 and ADAMTS-1.
Importantly, ADAMTS-1 has been reported to cleave the
ectodomain of syndecan-4, promoting migration in a way that
reflects genetic deletion of the proteoglycan (Rodríguez-Manzaneque
et al., 2009). However, wewere unable to detect evidence of a cleaved
form of syndecan-4 released from the fibroblasts and endothelial cells
used in our studies. Instead wewere able to demonstrate a convergent
functional relationship between ADAMTS-1 and syndecan-4 as
ADAMTS-1 siRNA treatment caused a significant reduction in
Fig. 4. ADAMTS-1 and SDC4 siRNA
treatment results in increased
angiogenesis. (A) Proliferation assay on
siRNA-treated ECs allowed incorporation
of BrdU for 12 h. Cells were fixed and
stained for BrdU and DAPI. Total number
of nuclei and BrdU-positive nuclei were
counted; bar chart shows the percentage
of proliferating cells (n=4; **P<0.01; NSD,
no significant difference). (B) 2D
migration assay on siRNA-treated ECs
seeded onto 10 µg/ml collagen I or
fibronectin matrix and allowed to adhere
overnight. Migration velocity was
determined with time-lapse microscopy
over a period of 16 h (n≥100 cells in four
independent experiments, charts show
means±s.e.m., **P<0.001). (C) TaqMan
qPCR of aortic rings treated with
ADAMTS1 or SDC4 siRNA showing
relative levels of SDC4 and ADAMTS-1 in
three independent experiments; bars
represent s.e.m., **P<0.001 compared
with control by Student’s t-test.
(D) Microvessel sprouting of aortic ring
explants from 6- to 8-week-old mice
treated with indicated siRNA. Aortae
were harvested from wild-type C56BL/6
mice in four independent experiments
(number of mice per experiments: 10, 8,
10 and 7). Aortae were stripped and cut
into rings that were equally distributed
between conditions. Representative
images of aortic rings stained with
fluorescein isothiocyanate (FITC)-
conjugated BS1-lectin are shown.
Images were obtained on an
epifluorescence microscope, and several
images were stitched in Fiji to give the
complete field of view, followed by
filtering to enhance. Scale bars, 200 µm.
(E) Bar chart showing the total number of
microvessel sprouts per aortic ring,
6 days post-VEGF stimulation (n≥50
rings per condition, n=4 independent
experiments of 10, 8, 10 and 7 mice. Bar
charts show means±s.e.m., **P<0.001,
***P<0.0001 compared with control rings
by Student’s t-test).
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syndecan-4 display at the cell surface, indicating that syndecan-4 is
dependent on ADAMTS-1. A key finding from our work is that this
connection between ADAMTS-1 and cell surface expression of
syndecan-4 involves matrix metalloproteinase-9 (MMP9).
Syndecan ectodomain shedding is an important regulatory
mechanism allowing for rapid changes in cell surface receptor
dynamics; shedding occurs juxtamembrane and can be carried out
by a number of matrix proteinases (Manon-Jensen et al., 2010).
MMP7 and MMP14 are both able to shed the extracellular domain
of syndecan-2, andMMP9 has been shown to shed syndecan-4 from
the cell surface in response to TNFα (Kwon et al., 2014; Lee et al.,
2017; Ramnath et al., 2014). There was a significant increase in
MMP9 expression in ADAMTS-1 siRNA-treated cells, and upon
loss of MMP9, via either an inhibitor or siRNA depletion,
syndecan-4 was no longer lost from the cell surface. We therefore
propose that the loss of ADAMTS-1 results in increased shedding of
syndecan-4 that is mediated by MMP9.
At this point, we are not able to identify the mechanism by which
ADAMTS-1 knockdown results in increased MMP9 expression. One
possibility, however, is that it occurs as a result of a shift in the
angiogenic signalling balance in endothelial cells. ADAMTS-1 is anti-
angiogenic, whereas MMP9 is highly pro-angiogenic, and can trigger
the ‘angiogenic switch’, a process in tumourswhere the balance of pro-
and anti-angiogenic factors swings towards a pro-angiogenic outcome
(Bergers et al., 2000). MMP9 promotes release of VEGF bound in the
matrix to heparan sulfate chains through cleavage (Hawinkels et al.,
2008). VEGF induces MMP9 expression, which leads to elevated free
VEGF levels resulting in a positive feedback loop (Hollborn et al.,
2007). Similarly, VEGF can up-regulate ADAMTS-1 expression,
suggesting a negative feedback mechanism at play (Xu et al., 2006). It
seems possible that loss of ADAMTS-1 disturbs the fine balance of
VEGF signalling, resulting in the cells switching to a more angiogenic
phenotype, and the up-regulation of MMP9.
We investigated the possibility that syndecan-4 works co-
operatively with ADAMTS-1 to inhibit angiogenesis through
sequestration of VEGF. This idea contrasts with several
hypotheses that syndecan-4 acts as a co-receptor for VEGF to
enhance signalling, as is the case for FGFs. Through co-
Fig. 5. siRNA depletion of ADAMTS-1 or SDC4
results in altered focal adhesions.
(A) Representative images of siRNA-treated ECs
adhered to fibronectin-coated glass coverslips for 90 or
180 min. Cells were fixed and stained for focal
adhesions with paxillin (green) and the nucleus with
DAPI (blue); n=3 independent experiments. Scale
bars, 10 µm. (B) Area of paxillin positive focal
adhesions, calculated using ImageJ. Graph shows
average size of adhesions, n=20 cells per condition
from three independent experiments, means±s.e.m.,
****P<0.00001, calculated using a Kruskal–Wallis test.
(C) Western blot analysis of paxillin signalling using an
anti-phospho-paxillin antibody in siRNA-treated ECs
adhered to fibronectin, serum starved for 3 h and then
stimulated with 30 ng/ml VEGF for 0, 5, 15 and 30 min.
GAPDH was used as a loading control; n=3
independent experiments.
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immunoprecipitations, we demonstrated that syndecan-4 does indeed
bind VEGF. We interpret this binding as sequestration, as an increase
in VEGF signalling and free VEGF is seen upon syndecan-4
depletion. These data strongly suggest that syndecan-4 does not
promote VEGF signalling, but instead alongside ADAMTS-1
sequesters VEGF to inhibit angiogenesis. We further demonstrated
this finding in a physiologically relevant ex vivo model of
angiogenesis and observed increased microvessel sprouting in an
aortic ring assay with ADAMTS-1 or syndecan-4 siRNA depletion. It
therefore seems plausible that MMP9, ADAMTS-1 and syndecan-4
work together in a complex equilibrium to balance VEGF
bioavailability and regulate angiogenesis.
For angiogenesis to occur, endothelial cells must proliferate and
migrate – processes that are heavily influenced by VEGF signalling.
Loss of ADAMTS-1 resulted in increased proliferation, although
this result was not mirrored by loss of syndecan-4. This implies that
the two molecules have distinct as well as shared actions. Syndecan-
4 is a major signalling nexus involved as a partner in the actions of
several growth factors as well as a source of intracellular signals
itself. These multiple pathways could negate the impact of
sequestration of VEGF by syndecan-4. Likewise, ADAMTS-1
functions independently of syndecan-4, specifically in relation to
angiogenesis by releasing anti-angiogenic peptides from TSP-1 and
TSP-2 through cleavage (Lee et al., 2006). At the organism level,
although Sdc4 and Adamts1 null mice share a delayed wound
healing response (Echtermeyer et al., 2001), the models do not
phenocopy each other. Whilst Sdc4 knockout mice are relatively
healthy, Adamts1 KO mice exhibit developmental issues with
Fig. 6. Depletion of ADAMTS-1 or SDC4 results
in downstream alterations to α5 integrin
behaviour. (A) Representative images of siRNA-
treated ECs adhered to fibronectin-coated glass
coverslips for 90 or 180 min. Cells were fixed and
stained for α5 integrin (green) and DAPI (blue);
n=3 independent experiments. Scale bars,
10 µm. (B) Representative western blot of IP
lysates from internalisation assays using an anti-
α5 integrin antibody. Cell surface proteins of ECs
seeded on fibronectin were biotinylated, and
allowed to internalise for 2, 4 and 10 min. Post-
internalisation, remaining surface biotin was
‘stripped’ using a membrane-impermeable
reducing agent (MesNa). Cells were lysed and
immunoprecipitated for biotin. The blot shows
‘total’ surface α5 (from cells not internalised and
not stripped), cells not internalised but ‘stripped’
as controls, and α5 internalisation at each time
point. (C) Quantification of α5 integrin
internalisation assays (n=3 independent
experiments). (D) Experiments from Figs 3D, 4B
and 5Bwere repeated in ECs isolated from α5 null
mice and their wild-type controls (n=3
independent experiments, charts show means±
s.e.m., *P<0.05, **P<0.01, ****P<0.00001,
compared with control cells by Student’s t-test).
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stunted growth and high embryonic mortality (Echtermeyer et al.,
2001; Shindo et al., 2000).
Previous work on fibroblasts from Sdc4−/− animals showed that
syndecan-4 was necessary for directional migration to occur (Bass
et al., 2007). However, in our experiments, acute depletion of
syndecan-4 or ADAMTS-1 in endothelial cells resulted in increased
migration speed. This observation was only seen on fibronectin, with
decreased or no change in migration speed on collagen. Fibronectin
matrix-dependent migration effects have been noted previously with
the ADAMTSs; work by Kelwick et al. showed that the closely related
ADAMTS-15 was able to inhibit MDA-MB-231 cell migration on
fibronectin matrices, and that this effect was dependent on syndecan-4
(Kelwick et al., 2015a). In endothelial cells, α5 integrin functions as
the major fibronectin receptor. Interestingly, syndecan-4 regulates
adhesion synergistically with fibronectin and α5β1 integrin (Morgan
et al., 2007), as well as regulating integrin trafficking. Phosphorylation
of syndecan-4 acts as a molecular switch, controlling levels of αVβ3
and α5β1 internalisation and recycling, and affecting cell behaviour
(Morgan et al., 2013).
Due to the clear connection between syndecan-4, fibronectin and
integrins, we sought to investigate α5 integrin as a potential mediator
of migratory effects. Immunocytochemical and cell surface
biotinylation data support an important role for syndecan-4 in
regulation of α5 integrin trafficking. ADAMTS-1 knockdown also
appeared to regulate α5 integrin trafficking, but whether this is a
direct effect is unclear, although it would be consistent with the
resulting loss of syndecan-4. Despite this, siRNA knockdowns of
ADAMTS-1 and syndecan-4 repeated in α5 null endothelial cells
Fig. 7. EC behaviour and signalling phenotypes are maintained in response to conditioned matrix. (A) Representative images of untreated ECs after
180 min on conditioned matrix (CM) from siRNA-treated ECs allowed to producematrix for 48 h before being removed. Cells were fixed and stained for α5 integrin
(green); n=3 independent experiments. Scale bars, 10 µm. (B) Western blot of untreated ECs seeded on CM for 45, 90 and 180 min, using anti-total (t) and
phosphorylated (p) FAK, ERK and paxillin. GAPDH was used as a loading control; n=3 independent experiments. (C) Western blot for fibulin-1 of siRNA-treated
ECs seeded onto fibronectin for 45, 90 or 180 min. GAPDH was used as a loading control. Blot is representative of three independent experiments.
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maintained the phenotypes of increased VEGF signalling, increased
free VEGF, faster random migration and larger focal adhesions,
suggesting that α5 integrin is not necessary for ADAMTS-1 and
syndecan-4 regulated angiogenesis and migration. Therefore, we
hypothesised that knockdowns of ADAMTS-1 and syndecan-4 may
result in ECM alterations, resulting in downstream changes to integrin
trafficking. Both proteins interact with the ECM: ADAMTS-1 is
secreted and anchors in the ECM, while syndecan-4 forms cell–ECM
attachments (Gopal et al., 2017; Kuno and Matsushima, 1998). In
support of this, non-treated naïve cells plated on ‘conditioned matrix’
generated by ADAMTS-1 and syndecan-4 siRNA-treated cells
behaved in a similar manner to siRNA-treated cells, forming
altered α5 adhesions, and displaying increased paxillin signalling.
Fibulin-1 is an ECM protein, and a co-factor for ADAMTS-1
(Lee et al., 2005); expression of fibulin-1 has been reported to result
in a fibronectin-specific inhibition of migration in a cell type-
dependent manner (Twal et al., 2001). In fibroblasts, this effect is
dependent on syndecan-4 (Williams and Schwarzbauer, 2009).
Fibulin-1 is indeed upregulated at 180 min post-adhesion in NTC-
treated cells, but not in ADAMTS-1 or syndecan-4 siRNA cells. We
therefore propose a mechanism for the control of migration in
endothelial cells where ADAMTS-1 and syndecan-4 regulate
production of fibulin-1, thereby suppressing migration and
facilitating α5 integrin turnover.
This work builds on the current literature on ADAMTS-1 as an
anti-angiogenic protein, demonstrating co-operation between
ADAMTS-1 and the heparan sulfate proteoglycan syndecan-4.
We also highlight a role for syndecan-4 in inhibiting migration and
angiogenesis, which contrasts with some previous published data.
Our studies therefore contrast with the work of Corti et al. (2019),
who found that endothelial specific knockout of syndecan-2 in mice
resulted in marked defects in angiogenesis, whereas knockout of
syndecan-4 resulted in no such defects. This specificity was
attributed to the enhanced 6-O-sulfation level in syndecan-2 versus
syndecan-4 heparan sulfate (HS) chains, leading to superior levels
of VEGFA165 binding by syndecan-2 versus syndecan-4 (Corti
et al., 2019). Two points are relevant in attempting to understand
data conflicts with regard to the role of syndecan-4 in angiogenesis
and migration. Firstly, it is important to consider the model used.
Much previous work has focused on the constitutive Sdc4-knockout
mouse, and cells and tissues isolated from it (Echtermeyer et al.,
2001). Compensatory mechanisms from developmental adaptation to
loss of syndecan-4 are possible, and may affect phenotypes, as
reported in a previous study (Bass et al., 2007). It is also now
recognised that passenger mutations in knockout mice created using
embryonic stem cells from the 129 strain may confound interpretation
of data from these mice (Eisener-Dorman et al., 2009). Secondly, in
our immortalised endothelial cell line syndecan-4 is the most highly
expressed member of the syndecan family, therefore its effects may
dominate. It seems likely therefore that both syndecan-2 and
syndecan-4 may contribute to VEGFA165 binding and angiogenesis.
There is also a potential argument that previous migration studies
had used fibroblasts derived from Sdc4-knockout mice, which may
be differently affected by loss of syndecan-4 than the VEGF-
responsive endothelial cells that are the focus of our work, due to the
involvement of syndecan-4 in multiple growth factor signalling
pathways. However, we have seen similar effects of siRNA-
mediated knockdown of syndecan-4 onmigration in fibroblasts as in
endothelial cells, suggesting that these are not dependent on cell
type. Our findings are lent support by work by Cavalheiro et al.,
who found increased migration speed when using short hairpin
RNA (shRNA) to deplete syndecan-4 in endothelial cells
(Cavalheiro et al., 2017). In future, the field could be greatly
advanced by development of an endothelial specific syndecan-4
conditional knockout mouse that would aid in resolving issues of
redundancy and compensation.
In conclusion, our work shows that ADAMTS-1 regulates cell
surface expression of syndecan-4, and in endothelial cells both
molecules act via sequestration of VEGF and inhibition of
angiogenesis. ADAMTS-1 influences syndecan-4 levels on the cell
surface via regulation of MMP9 production. Our studies lead to a
proposed model of convergent roles for ADAMTS-1 and syndecan-4
in regulating the ECM, inhibiting migration, modulating integrin
adhesions and activating the matrix protein fibulin-1 (Fig. 8).
MATERIALS AND METHODS
Animals
All animal experiments were performed in accordance with UK Home
Office regulations and the European Legal Framework for the Protection of
Animals used for Scientific Purposes (European Directive 86/609/EEC).
Cell culture and isolation
Human umbilical vein endothelial cells (HUVECs) were purchased from
Lonza (Basel, Switzerland), and cultured in EBM-2 medium supplemented
with the SingleQuots kit (Lonza). 3T3 fibroblasts were cultured in high-
glucose Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen)
supplemented with 10% fetal bovine serum (FBS) (HyClone, Invitrogen),
100 units/ml penicillin/streptomycin (Invitrogen), and 2 mM GlutaMAX
(Invitrogen).
Primary mouse lung endothelial cells were isolated from adult mice
as previously described by Reynolds and Hodivala-Dilke (2006). For
immortalisation, ECs were treated with polyoma-middle-T-antigen (PyMT)
retroviral transfection, as described by Robinson et al. (2009). Immortalised
mouse lung endothelial cells (ECs) were cultured in IMMLEC medium, a
1:1 mix of Ham’s F-12–DMEM medium (low glucose) supplemented with
10% FBS, 100 units/ml penicillin/streptomycin, 2 mM GlutaMAX and
50 μg/ml heparin (Sigma).
All cells were cultured at 37°C in a humidified chamber with 5% CO2. Cells
were routinely screened for mycoplasma contamination. For experimental
analyses, plates and flasks were coated with either human plasma fibronectin
(FN; Millipore) or collagen I (Col I; Fisher Scientific, Loughborough, UK)
overnight at 4°C. VEGF-A 164 (henceforth referred to as VEGF) was made
in-house according to the method published by Krilleke et al. (2007).
Fig. 8. Proposedmodel of interaction between ADAMTS-1 and syndecan-4.
Schematic outlining the interactions and functions of ADAMTS-1and syndecan-4
in endothelial cells. Figure created using BioRender.
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RNAi and lentiviral transfections
For siRNA transfections, ECs were transfected with 50 nM siRNA (Thermo
Fisher Scientific) using the Amaxa nucleofector system (Lonza) according
to the manufacturer’s instructions, with a final siRNA concentration of
50 nM, and the nucleofection program T-005. For syndecan-4 (SDC4) ICC
and ELISA, ECs were transfected with HA-tagged SDC4 construct (a
generous gift from Dr. James Whiteford, Barts and the London School of
Medicine and Dentistry, Queen Mary University of London, London, UK).
Transfected cells were selected using a GFP reporter tag.
For shRNA knockdown of syndecan-4 and ADAMTS-1 in HUVECs,
packaging plasmids (Addgene, #12260 and #12259) were mixed with
shRNA plasmid (Mission shRNA, Sigma-Aldrich) in Optimem medium
(Invitrogen) and Lipofectamine 2000 (Invitrogen) with the following ratios:
750 ng psPAX2, 250 ng pMD2.G and 1 μg shRNA. The mixture was
transferred to 80% confluent 293T cells in 10 cm dishes for 6 h. The
medium was replaced with regular DMEM 10% FBS and collected after
48 h. Medium containing virus was filtered through a 0.45 μm filter and
used for HUVEC transduction with the addition of 8 μg/ml polybrene
(Sigma). The target sequences used were as follows: human Sdc4 sequence:
5′-CCGGCCTGATCCTACTGCTCATGTACTCGAGTACATGAGCAG-
TAGGATCAGGTTTTTG-3′. human Adamts1 sequence: 5′-CCGGCCA-
CAGGAACTGGAAGCATAACTCGAGTTATGCTTCCAGTTCCTGTG-
GTTTTTG-3′.
Flow cytometry
For flow cytometric analysis, cells were removed from culture plates using
citric saline buffer (1.35 M KCl, 0.15 M Na3C6H5O7). Cells were collected by
centrifugation and resuspended in fluorescence-activated cell sorting (FACS)
buffer [5% FBS in phosphate-buffered saline (PBS)] and labelled with anti-
mouse syndecan-4 (KY/8.2, BD Biosciences, Allschwil, Switzerland), or
isotype control (mouse IgG2a, Invitrogen) for 1 h. Cells were washed,
resuspended in FACS buffer and incubated with fluorophore-conjugated
secondary antibody (eBioscience, San Diego, CA, USA). Data were collected
using a Beckman CytoFLEX flow cytometer and analysed using FlowJo.
For treatment with MMP inhibitors one of: 5 μM BB-94 (Abcam,
Cambridge, UK), 10 μM CT1746 (CellTech, Slough, UK), 10 μM GM-
6001 (Millipore) in 10 μl DMSO, or DMSO vehicle control, was added to
cells for 18 h prior to flow cytometric analysis.
RNA extraction, RT-PCR and real-time quantitative RT-PCR
analyses
Total cell RNA was extracted using the SV Total RNA Isolation Kit
(Promega) according to the manufacturer’s instructions. RNA samples were
reverse transcribed using the GoScript Reverse Transcriptase system
(Promega). Quantitative real-time TaqMan PCR was carried out as
described previously (López-Otín and Matrisian, 2007).
Immunocytochemistry
siRNA-transfected ECs were seeded at a density of 2×105 cells per well in
24-well plates on acid-washed and oven-sterilised glass coverslips pre-
coated with FN or Col I. Cells were fixed at indicated time points in 4%
paraformaldehyde, washed in PBS, blocked and permeabilised with 0.3%
Triton X-100, 10% serum, and incubated with primary antibody diluted
1:100 in PBS for 1 h at room temperature (RT). Primary antibodies were:
anti-HA tag (1:100; 2-2.2.14; Thermo Fisher Scientific), anti-paxillin
(ab32084; Abcam) and anti-α5 integrin (1:100; ab150361; Abcam).
Coverslips were washed with PBS, and incubated with the relevant Alexa-
Fluor-conjugated secondary antibody (Invitrogen) diluted 1:500 in PBS for
45 min at RT. Coverslips were washed in PBS again, before mounting on
slides with ProLong Gold containing DAPI (Invitrogen). Focal adhesion
area calculations were carried out using Fiji software.
Internalisation and recycling assays
Internalisation
siRNA transfected cells (1×106) were seeded in 10 cm dishes. After adhering
overnight, cells were serum starved for 3 h, transferred to ice, washed twice in
cold PBS, and surface labelled at 4°C with 0.3 mg/ml NHS-SS-biotin (Pierce)
for 30 min. One dishwas collected prior to internalisation, to allow comparison
of internalised protein versus total cell surface. Labelled cells were washed in
cold PBS and transferred to IMMLEC at 37°C to allow internalisation. At each
time point, medium was removed, dishes were transferred to ice and washed
twice with ice-cold PBS. Biotin was removed from proteins remaining at the
cell surface by incubation with the membrane-impermeable reducing agent
MesNa (20 mM MesNa in 50 mM Tris–HCl; pH 8.6) for 1 h at 4°C. MesNa
was quenched by the addition of 20 mM iodoacetamide (IAA) for 10 min.
Cells were lysed in 200 mM NaCl, 75 mM Tris, 15 mM NaF, 1.5 mM
Na3VO4, 7.5 mM EDTA, 7.5 mM EGTA and 1.5% Triton X-100,
supplemented with protease inhibitor (Merck). Lysates were cleared by
centrifugation at 10,000 g for 10 min. Levels of syndecan-4 internalisation
were determined by capture ELISA. For α5 integrin internalisation analysis,
biotinylated protein was isolated by immunoprecipitation using anti-biotin
(Jackson ImmunoResearch), and levels ofα5 integrin assessed by SDS-PAGE.
Recycling
After surface labelling, cells were incubated in IMMLEC at 37°C for 20 min
to allow internalisation. After internalisation a plate was collected to allow
quantification of recycled protein versus total internalised. Following
removal of biotin from surface proteins using MesNA, the internalised
fraction was then allowed to recycle to the membrane by returning cells to
37°C in IMMLEC. At the indicated times, cells were returned to ice and
biotin was removed from recycled proteins by a second reduction with
MesNa. Biotinylated syndecan-4 was then determined by capture-ELISA.
Capture-ELISA
Microplates (96-well; R&D Systems) were coated overnight with 5 μg/ml
HA-tag antibody (1:1000; 51064, Proteintech) in PBS at RT. The plates
were blocked in PBS containing 0.05% Tween-20 (0.05% PBS-T) with 1%
BSA for 1 h at RT. HA-SDC4 was captured by 2 h incubation of 100 μl cell
lysate (1 μg/μl) at RT. Unboundmaterial was removed by extensive washing
with 0.05% PBS-T. Wells were incubated with streptavidin-conjugated
horseradish peroxidase (R&D Systems) in 0.05% PBS-T containing 1%
BSA for 1 h at RT. Following further washing, biotinylated SCD4 was
detected with tetramethylbenzidine (R&D Systems).
Zymography
Zymography was performed using SDS-PAGE (7.5%) gels co-polymerised
with 1 mg/ml gelatin. Protein concentrations of media samples were
equalised, and added to 5× non-reducing sample buffer (Thermo Fisher
Scientific). After electrophoresis, gels werewashed twice for 30 min in wash
buffer (2.5% Triton X-100, 50 mM Tris–HCl, 5 mMCaCl2, 1 μMZnCl2) at
RT. Gels were incubated overnight in incubation buffer (1% Triton X-100,
50 mM Tris–HCl, 5 mM CaCl2, 1 µM ZnCl2) at 37°C. Gels were stained in
Coomassie Blue R 250 (Thermo Fisher Scientific) in a mixture of methanol:
acetic acid:water (4:1:5) for 1 h and destained in the same solution without
dye. Gelatinase activities were visualised as distinct bands.
Western blot analysis
ECswere seeded at 2.5×105 cells per well in 6-well plates coatedwith 10 μg/ml
FN. After 24 h, cells were starved for 3 h in serum-free medium (Opti-MEM;
Invitrogen). VEGF was then added to a final concentration of 30 ng/ml. Cells
were lysed at the indicated times (Fig. 3) in radioimmunoprecipitation assay
(RIPA) buffer [25 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5%
sodium deoxycholate, 1% Triton X-100, supplemented with protease inhibitor
(Merck)]. After protein quantification using the DC Bio-Rad assay, 30 μg of
protein from each samplewas loaded onto 8%polyacrylamide gels. For paxillin
analysis, samples were loaded onto a 4–12% gradient gel for better resolution.
The protein was transferred to a nitrocellulose membrane and incubated for 1 h
in 5% milk powder and PBS plus 0.1% Tween-20 (0.1% PBS-T), followed by
an overnight incubation in primary antibody diluted 1:1000 in 5% bovine
serum albumin (BSA) and 0.1% PBS-T at 4°C. The blots were then washed
three times with 0.1% PBS-T and incubated with the relevant horseradish
peroxidase (HRP)-conjugated secondary antibody (Dako, Santa Clara, CA,
USA) diluted 1:2000 in 5% milk and PBS-T, for 1 h at room temperature.
Chemiluminescence was detected on a Bio-Rad Gel Doc XR+ (Bio-Rad).
Antibodies (all used at 1:1000 and purchased from Cell Signaling
Technology, unless noted otherwise) were: anti-phospho (Y1175) VEGFR2
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(clone 19A10); anti-VEGFR-2 (clone 55B11); anti-phospho (Thr202/
Tyr204) p44/42MAPKErk1/2 (clone D13.14.4E); anti-total p44/42MAPK
Erk1/2, anti-HSC70 (clone B-6, Santa Cruz Biotechnology), anti-human
syndecan-4 (ab24511, Abcam), anti-phospho (Tyr118) paxillin (2541),
anti-phospho (Tyr925) focal adhesion kinase (FAK), anti-FAK and
anti-GAPDH (6C5, Abcam).
Fiji software (https://imagej.net/Fiji) was used for quantification of band
densities.
Immunoprecipitation assay
HUVECs were grown to 80–90% confluency in 10 cm dishes coated with
10 μg/ml FN in PBS. Cells were lysed in RIPA buffer. Four hundred
micrograms of total protein from each sample was immunoprecipitated by
incubation with protein G Dynabeads (Invitrogen) coupled to 1 μg mouse-
anti-human VEGF-A antibody (VG-1, Abcam) on a rotator overnight at
4°C. Immunoprecipitated complexes werewashed three times with 0.2 ml of
RIPA buffer, and once in PBS, before being added to, and boiled in
NuPAGE sample reducing agent and sample buffer (Life Technologies) for
western blotting.
VEGF ELISA
For quantification of free VEGF present in the media, ECs were plated at a
density of 2.5×105 cells per well of a 6-well plate. Cells were chilled to 4°C,
medium was removed and cells were washed twice in ice-cold PBS.
Medium was replaced with ice-cold Opti-MEM containing VEGF at a final
concentration of 30 ng/ml. Media were diluted 1:10 in 1% BSA in PBS, and
VEGF concentration was quantified using a mouse VEGF duo-set ELISA,
according to the manufacturer’s instructions (DY493, R&D Systems).
Proliferation assay
siRNA-transfected ECswere seeded onto 10 μg/ml FN-coated glass coverslips
(1.5×104 cells per well of a 24-well plate). After 4 h, the mediumwas replaced
with IMMLEC containing 10 nM BrdU. After 12 h cells were fixed in 4%
paraformaldehyde. To stain, cells were incubated in 1 MHCl for 30 min at RT,
then permeabilisedwith PBS 0.25%TritonX-100 for 10 min and blocked by a
20 min incubation in Dako block (Agilent). BrdU was detected by incubation
with anti-BrdU (ICR1, Abcam) diluted 1:100 in PBS for 1 h at room
temperature. Coverslips were washed in PBS, then incubated with anti-sheep
Alexa-Fluor (Invitrogen) for 1 h at RT. After further PBS washes, coverslips
were mounted in ProLong Gold containing DAPI (Invitrogen).
Random migration assay
siRNA-transfected ECs were trypsinised and seeded at 1.5×104 cells per
well in 24-well plates coated with 10 μg/ml FN or 10 μg/ml Col I in PBS,
and allowed to adhere overnight. The medium was then replaced with fresh
IMMLEC. One phase contrast image per well was taken live every 10 min in
a fixed field of view using an inverted Axiovert microscope (Zeiss) for 16 h
at 37°C and 5% CO2. Individual cells were then manually tracked using the
Fiji cell tracking plug-in, mTrackJ (https://imagej.net/MTrackJ) and the
speed of randommigration was calculated in nanometres moved per second.
Ex vivo aortic ring assay
Thoracic aortae were isolated from 6- to 8-week-old adult C57BL/6 mice
and prepared for culture as described extensively by Baker et al. (2012).
Syndecan-4 or ADAMTS-1 depletion was induced using 1 μM siRNA
and oligofectamine. Where indicated, VEGF was added at 30 ng/ml.
Microvessel growth of aortic rings was quantified after 6–10 days.
Conditioned matrix generation
For experiments using conditioned matrix (CM), siRNA-treated cells were
seeded at ∼70% confluence and allowed to produce matrix for 48 h. Plates
were washed in PBS and cells were removed by incubation in 20 mM
ammonium hydroxide. After extensive washing in PBS, untreated cells
could then be seeded onto the CM.
Statistics
Statistical analysis was conducted in R. Graphing was conducted in R or
GraphPad. Where data were normally distributed with equal variance, a
Student’s t-test was used to determine statistically significant differences
between conditions. Normal distributions were tested for using a Shapiro–
Wilk test. Where data did not fit the normal distribution (focal adhesion
sizes) a Kruskal–Wallis non-parametric test was used to determine statistical
significance. Bar charts represent the mean and the standard error of the
mean (s.e.m.), unless otherwise stated. Asterisks represent P-values as
follows: *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001.
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